H]farnesyl diphosphate (FPP) or [
3 H]geranylgeranyl diphosphate (GGPP) as prenyl donor. The other two methods involving radioactivity (in vitro transcription/translation and labeling of cells with [ 3 H]MVA) are designed to establish whether or not a candidate PT substrate undergoes prenylation in vitro and in intact cells, respectively, and to determine the effects of PTIs on this prenylation. We also describe two other assays that take advantage of the fact that, for most proteins, inhibition of prenylation results in slower electrophoretic mobility or, alternatively, relocation to cellular membranes. These techniques can be used to answer, either directly or indirectly, the following important biological questions facing the area of prenylation research. Is a (novel) protein of interest a substrate for FT and/or GGT-1? Can this protein be modified by prenylation in vitro [1] [2] [3] and in whole cells 4 ? This is important, because for reasons discussed above, it is very likely that not all proteins regulated by prenylation have been identified yet.
Can PTIs be developed either as chemical probes or potential anticancer agents? To function as chemical probes, PTIs have to meet the criterion that they inhibit selectively their intended target. This is initially established using in vitro PT activity assays with purified or partially purified enzymes [5] [6] [7] [8] . To function as anticancer agents, they must successfully pass a number of tests, which include inhibiting their targets in whole cells [7] [8] [9] [10] or tissue [11] [12] [13] , inhibiting anchorage-dependent or anchorage-independent cell Measurement of protein farnesylation and geranylgeranylation in vitro, in cultured cells and in biopsies, and the effects of prenyl transferase inhibitors number of proteins being prenylated in vivo (i.e., the prenylome) is unknown 43, 44 ; however, although more than 100 proteins have experimentally been shown to undergo prenylation 32 , contemporary reviews estimated several hundred proteins to be subject to prenylation 33, 45 . A search of the most recent UniProtKB/SwissProt database (released 20 April 2010) has returned 587 human genes that potentially encode proteins bearing a C-terminal CXXX motif (N.B. and S.M.S., unpublished results), suggesting that many prenylated proteins have not been identified yet. Not surprisingly then, genetic disruption of FT has further suggested a critical role for farnesylation: FT knockout mice die early in embryonic development 46 . However, in conditional knockout mice, FT is dispensable for postnatal development and adult tissue homeostasis. Furthermore, FT is not required for tumor initiation, but for tumor progression and maintenance. Perhaps most importantly, in the conditional absence of FT, the FT substrate protein H-Ras is still associated with cellular membranes 46 , contradicting earlier studies in whole cells demonstrating that farnesylation is required for H-Ras membrane association 47 , and a non-prenylatable mutant of H-Ras exclusively resides in the cytosolic fraction 48 . However, these results have been challenged by two more recent studies. First, the FT null allele generated by Mijimolle et al. 46 may have been 'leaky' , allowing for expression of partially active FT 49 . Second, in mice with a conditional FT deletion, H-Ras fails to associate with membranes 50 , thus confirming a variety of earlier studies in whole cells 48, 51, 52 . Although conditional GGT-1 knockout studies were reported (see below), whether constitutive ablation of GGT-1 in mammals is also embryonically lethal has not been determined yet. However, studies conducted in both Saccharomyces cerevisiae 53 and Drosophila 54 suggest that the GGT-1 β-subunit is an essential protein.
After the discovery that Ras is farnesylated 2 and that farnesylation is required for its transforming activity 55 , FT and GGT became major targets for developing anticancer drugs. Besides Ras, many PT substrates are involved in regulating cell growth, proliferation and survival, as well as migration, invasion and metastasis 56 . These include small GTPases of the Rac, Rho, Rheb and Ral subfamilies, as well as transducin, the γ subunits of trimeric G protein and lamins. Ras can activate at least 11 signal transduction As described in the text and summarized here, proteins undergoing prenylation typically bear a C-terminal CaaX consensus sequence. Mutants that either convert the protein of interest from an FT into a GGT-1 substrate (or vice versa) or render them resistant to prenylation are of great value for prenylation research. To name just one example, prenylation-resistant mutants can be used to determine whether prenylation is required for a phenotype associated with the protein in question. See Figure 5 for an example.
pathways, some of which are well documented to contribute to malignant transformation, including the Raf-MEK-ERK 57 , phosphoinositide 3-kinase/Akt 58 , Ral GDS-Ral, TIAM1-Rac and Rho-ROCK pathways (reviewed in refs. 59, 60) . Thus, it is not surprising that many of these prenylated proteins promote and/or maintain malignant transformation.
Preclinical and clinical activity of farnesyltransferase inhibitors
In well-defined systems in which mutant H-Ras drives the transformation of NIH 3T3 cells, FTIs inhibit the farnesylation of H-Ras, prevent its plasma membrane association and inhibit downstream signal transduction pathways, such as Raf-MEK-ERK, leading to inhibition of tumor growth 47, 61 . Similarly, FTIs induce breast tumor regression in mutant H-Ras transgenic mice, but only tumor-growth inhibition in mutant K-Ras transgenic mice 62, 63 . In human tumor cell lines with multiple genetic alterations, FTIs inhibit proliferation and/or induce apoptosis (reviewed in refs. 45, 64, 65) , and in most cell lines this is associated with mitotic arrest [66] [67] [68] , but occasionally with G1 phase accumulation 69 . Consistent with the fact that K-Ras is geranylgeranylated in FTI-treated cells and is fully functional 39 , the sensitivity of human cancer cells to FTIs does not depend on K-Ras mutation status 9 , suggesting that FTIs have at least one other critical farnesylated target that is responsible for limiting tumor cell proliferation and/or survival. Inhibition of RhoB farnesylation, which results in accumulation of geranylgeranylated RhoB has been suggested as a potential contributor 14, 70 , but the fact that both farnesylated and geranylgeranylated RhoB have tumor-suppressive activity argues against this 71 . Inhibition of Rheb, a GTPase that stimulates mammalian target of rapamycin (mTOR), has also been suggested as a critical FTI target 24 , but more direct evidence for this is required. In mice, the antitumor activity of FTIs is evident when used as single agents, but is enhanced in combination with other antisignaling agents such as inhibitors of MEK, CDKs or BcrAbl kinase, as well as cytotoxic agents such as paclitaxel, cisplatin and 5-fluorouracil (reviewed in ref. 65 . However, in more recent phase 2 clinical studies with locally advanced breast cancer patients, the addition of tipifarnib to standard chemotherapy (adriamycin and cyclophosphamide) improved the pathological complete response rate of these patients 75 .
Geranylgeranyltransferase 1 inhibitors
The development of GGTIs as potential anticancer agents was prompted by the fact that K-Ras becomes geranylgeranylated under FTI pressure and that in some human malignancies such as pancreatic cancer, pathways mediated by geranylgeranylated proteins such as RalA and RalB may be more relevant to oncogenesis than those mediated by MEK or Akt 76, 77 . However, unlike FTIs, human cancer cells treated with GGTIs undergo G1 phase arrest [78] [79] [80] . Consistent with this, GGTIs induce p21 expression, inhibition of CDKs and hypophosphorylation of pRb 78 . Furthermore, GGTIs induce the accumulation of p27 in the nucleus by a mechanism that involves inhibition of CDK2 phosphorylation of Thr187 in p27 (ref. 18) . GGTI-mediated induction of apoptosis may be associated with their ability to reduce phospho-Akt and survivin levels 81 . Furthermore, the ability of GGTIs to induce apoptosis and inhibit anchorage-independent growth has been suggested to depend on their ability to inhibit the geranylgeranylation of RalB and RalA, respectively 3 . In mice, conditional GGT-1 deficiency 82 or conditional simultaneous knockout of both FT and GGT-1 (ref. 50 ) markedly reduces the formation of K-Ras-induced lung cancer and also extends the life span of these mice. Using pharmacological inhibition of GGT-1, our laboratory has recently demonstrated that GGTI-2418 effectively prevents tumor growth in nude mice and results in breast tumor regression in transgenic mice expressing ErbB2 (ref. 18 ). GGTI-2418 has recently entered phase 1 clinical trials 83 .
Experimental design
In Figure 1 , we present a flow diagram that presents the key steps of the methods described below. As we describe several alternative methods to characterize protein prenylation, our protocol basically consists of only two major steps. The first is the preparation of the source material ((A) In the first part of Step 2 (Step 2A in Fig. 1 ), we describe two conceptually distinct methods for determining PT enzymatic activity. The first method is designed to measure the inhibitory activity of PTIs, including their IC 50 values, using purified FT or GGT-1 (both of which are commercially available). The second method is a variation of the first that is designed to quantify PT enzymatic activity in cultured cells, organs, tumors or blood cells from animals or humans that have been treated with a PTI. We have used this technique with cultured cells 84 , PBMCs 28 and tumor biopsies from mice 80 or humans 30 . Furthermore, this assay can be adapted to measure the activity of PTIs using FT or GGT-1 isolated from untreated normal cells, cancer cells or tumors. The concentration range of the PTI investigated should initially be broad and/or based on results obtained from prior high-throughput screens. We typically cover the low-nanomolar to midmicromolar range, using concentrations from 1 nM up to 300 µM, in Steps 1-3 and 10-30 (and so on). This parameter may have to be optimized further. We have used this protocol to evaluate CaaX peptidomimetics 85, 86 , nonpeptide Ras-CaaX mimetics 87 , FTI-244 (ref. 88) , FTI 276/277 and GGTI-286/287 (refs. 47,89) , whereas others have used the same or similar assays to characterize the potency and specificity of the FTIs Lonafarnib 66 and BMS-214662 (ref. 90) . In both cases, [ 3 H]-labeled FPP and GGPP are used as the farnesyl or geranylgeranyl donors. To measure FT activity, we routinely use purified recombinant wild-type H-Ras, which has the C-terminal tetrapeptide sequence CVLS. To measure GGT-1 activity, we use a mutant H-Ras in which the C-terminal serine is replaced by leucine; this is followed by expression in Escherichia coli 91 and purification of the recombinant mutant H-Ras protein. These recombinant protein substrates can be made in-house, but they are also commercially available.
The second part of Step 2 of this protocol describes assays for the protein prenylation state of individual proteins (Fig. 1 ) from cultured cells (options B-D), and from PBMCs, normal tissue and tumor biopsies (options B-C). In contrast to protein phosphorylation, antibodies recognizing unique prenylation motifs are not available. Therefore, many of the current techniques rely on more indirect methods or the use of radiochemicals to investigate protein prenylation. Three approaches are possible:
(1) Western blotting to demonstrate change in apparent M r upon inhibition of prenylation (EMSA, Step 2B in Figure 1 ). (2) Subcellular fractionation, followed by western blot to demonstrate association with cell membranes upon prenylation, or association with the cytosolic fraction upon inhibition of prenylation ( Step 2C in Fig. 1 ). The first approach takes advantage of the fact that most proteins migrate faster and decrease their apparent M r upon prenylation. This would be the method of choice because it is straightforward and takes the least amount of time. The even easier use of prenylation state-specific antibodies in western blots would also fall into this category. Antibodies to non-farnesylated prelamin A have been described 92 , but to our knowledge the only antibody that is specific for an unprocessed PT substrate and commercially available is sc-1482 from Santa Cruz, which recognizes unprocessed Rap1A. As other PTMs such as phosphorylation are associated with changes in apparent M r , it is important not to rely solely on this approach to determine whether a protein is prenylated. This is especially true when studying novel candidates for prenylation. We have used this technique, also termed EMSA, with all three isoforms of Ras 47, 61, 89, 93 , Rap1A 11, 21, 78, 93, 94 , RhoA Steps 2A-C are designed to determine either PT activity or the prenylation state of select proteins in response to prior exposure to a PTI. Steps 2D-E are primarily designed to determine whether or not a candidate protein undergoes prenylation in intact cells (2D) or in vitro (2E), but they can also be done in the presence or absence of previous drug treatment.
The second strategy is based on the fact that prenylation often leads to association of the protein being prenylated with cellular membranes. This strategy is recommended in cases in which a shift in apparent M r upon prenylation is either lacking or too small to resolve by standard electrophoretic procedures, e.g., for RhoA 18, 79 . This approach consists of preparing membrane and cytosolic fractions by subcellular fractionation techniques, followed by western blotting for the protein being studied. A previous exposure of the cells to a PTI should thus result in a cytosolic accumulation of the protein of interest. Membrane association or the lack thereof can alternatively be demonstrated by immunofluorescence 3, 57, 97 or fluorescence resonance energy transfer 98, 99 . As these procedures are well established and not unique to prenylated proteins, we have not described them in detail here.
As controls for the two strategies above, we recommend the following. For a novel PTI, one should ideally use a closely related molecule that has been demonstrated to be inactive in vitro as a negative, and a 'tried and tested' PTI as a positive, control. Regardless of the identity of the protein being studied, one should probably test the effects of FTIs or GGTIs on the behavior of HDJ-2 (exclusively farnesylated) and Rap1 (exclusively geranylgeranylated) proteins in the final read-out.
The third approach relies on labeling cells with [ 3 H]MVA, which is a C 6 precursor of C 5 isopentenyl diphosphate. Isopentenyl diphosphate is then sequentially polymerized to yield C 10 geranyl, C 15 farnesyl and C 20 geranylgeranyl diphosphates, the last two of which are the precursors of protein-bound isoprenyl groups. To ensure maximum labeling with [ 3 H]MVA, it is advisable to deplete unlabeled endogenous MVA with an inhibitor of hydroxymethyl glutaryl-coenzyme A reductase, the enzyme generating MVA from hydroxymethyl glutaryl. In addition, using medium containing dialyzed serum will aid in further reducing the endogenous MVA pool. Provided an antibody capable of immunoprecipitating the native protein of interest is available, this would permit the investigation of endogenously expressed proteins. In case such antibodies are unavailable, an alternative approach is to ectopically express the protein carrying an N-terminal epitope tag. The immunoprecipitated protein is then separated by SDS-PAGE, followed by electrotransfer to PVDF membranes and autoradiography. This approach, although it is the most elaborate and possibly most time consuming because of potentially lengthy exposure times of membranes to X-ray film, is the most direct evidence for prenylation in intact cells and is most suitable to establish that a protein previously unknown to undergo prenylation is subject to this PTM. In 1990, this approach has been successfully used to show that K-Ras is isoprenylated 55 . More recently, variations of this technique have been used to determine that in intact cells, lamin B is farnesylated 9 and the F-box protein FBXL2 is geranylgeranylated 4 . In all of the methods of the second part, the following experimental parameters may need to be optimized because they are dependent on the cell line, the protein or the effects of the PTI being studied: size of cell culture plate, initial cell density, incubation time and PTI concentrations. The determining factor here is to obtain enough samples to detect the protein of interest. Many laboratories, including our own, typically conduct other assays designed to measure cellular phenotypes in response to PTIs, e.g., cell viability, cell death and cell proliferation. These assays have to be set up in parallel sister cultures and will not be covered here.
A fourth and last approach is a method to assess the degree of prenylation of a protein of interest using in vitro transcriptiontranslation systems ( Step 2E, Fig. 1 35 S]methionine in order to assess the protein levels generated during the translation reaction. Finally, we emphasize the significance of farnesylation-, geranylgeranylation-and prenylation-resistant mutants as valuable research tools in this field ( Table 1) . Although they are not covered in detail in the protocols described below, these mutants enable us to ask important questions. For example, if one mutates a GGT-1 substrate into an FT substrate, prenylation of such a mutant should be resistant to GGTIs and ectopic expression of such mutant should rescue cells from GGTI effects. Similarly, an FT substrate protein mutated into a GGT-1 substrate should be resistant to FTIs and should rescue cells from FTI-induced effects. These exclusively farnesylated or exclusively geranylgeranylated proteins are generated by converting the C-terminal residue into methionine (for FT) or leucine (for GGT-1). For an example of how we used these mutants in defining the roles of RalA and RalB in transformation, see ref. 3 . Finally, rendering a protein prenylation resistant is crucial to link prenylation to a cellular phenotype. These mutants are generated by replacing the prenylatable cysteine with serine. This approach was used to demonstrate that farnesylation is required for the transforming activity of K-Ras 55 .
Limitations of the protocols
In summary, although the methods described here were developed more than 15 years ago, they are still appropriate for quantifying PT enzyme activities and for studying prenylation events of single proteins. To our knowledge, there are no alternative methods available to the PT activity assays we describe, except mass spectrometry (see below). The strategies described here are invaluable to establish that a given PTI has inhibited its primary target, i.e., either FT or GGT-1, or prevented the prenylation of select FT or GGT-1 substrates. Because PTIs affect possibly hundreds of PT substrates, a general disadvantage of these methods is that they cannot unequivocally establish a link between the biochemical effect on a certain protein and the effect on a cellular phenotype of a given PTI. One possible approach to overcome this conundrum is to use small interfering RNAs silencing prenylated proteins that are suspected to be responsible for mediating the PTI effects.
A specific disadvantage of the EMSA and the subcellular fractionation assay is that the former only works for proteins in which the prenylation status changes their apparent Mr, and the latter only works for proteins that accumulate in the cytosol in response to a PTI. For newly identified PT substrates, this needs to be established first in order to take advantage of these methods.
A key drawback of the method designed to investigate candidate proteins for prenylation (Steps 1D and 2D) is the length of time required for autoradiography. Provided the sequence of the candidate protein is known, a nonradioactive alternative would be to subject the immunoprecipitated candidate protein to proteolytic digestion and to analyze the resulting C-terminal peptides by mass spectrophotometry.
The most important limitation of these methods is that they appear unsuitable to investigate prenylated proteins on a larger, maybe even proteome-wide scale, in a timely manner. Such approaches are urgently needed in order to identify the subsets of prenylated proteins that are affected by FTIs and/or GGTIs, which in turn should help to link the physiological effects of various PTIs to their molecular targets, and thus design improved clinical trials. Maurer-Stroh et al. recently made an important step toward this goal when they developed a software that predicts whether a protein can potentially be prenylated. This takes into account the requirement for specific residues within the CaaX box, evolutionary conservation of the prenylation motif across phyla and physicochemical constraints extending up to 11 residues upstream of the prenylatable Cys 43, 44 . The same laboratory also described in vitro prenylation assays based on incubation of target proteins expressed in rabbit reticulocyte lysates with 3 H-labeled prenyl precursors and subsequent analysis by thin-layer chromatography, which bypasses the long exposure times required for 3 H-autoradiography 100 . Another encouraging approach to identify prenylated proteins is to use modified prenyl donors containing antigenic or chemoselective groups that can be exploited for subsequent detection. Such a technique, incorporating the use of a synthetic azido-farnesyl analog and affinity purification by a biotinylated phosphine capture reagent, led to the proteomic identification of 18 farnesylated proteins 101 . This so-called 'tagging-via-substrate' approach has recently been developed further by Onono et al. 102 , who labeled cells with anilinogeraniol, an alcohol precursor of an unnatural prenyl donor, i.e., 8-anilinogeranyl diphosphate. Cell lysates were then analyzed by 2D-PAGE and western blotting with antibodies to anilinogeranyl, thus identifying the farnesylated prenylome 102 . Another significant advance was presented by Nguyen et al. 103 , who used biotinylated geranyl diphosphate (BGPP) as a lipid donor for GGT-2. As neither FT nor GGT-1 accepts BGPP as a substrate, the authors modified the prenyl donor site of both enzymes, enabling them to recognize BGPP. Using either wild-type GGT-2 or modified FT and GGT-1 together with BGPP, protein substrates can be biotinylated, isolated from cell lysates by streptavidin beads and identified by proteolytic digestion and analysis by tandem mass spectrometry 103 . These novel techniques and others [104] [105] [106] have recently been reviewed in ref. 107 .
MaterIals

REAGENTS
Step 1A and 1D (mammalian cell culture) Complete tissue culture medium appropriate for the cells being studied (various suppliers) FBS (heat-inactivated at 56 °C, triple 0.1 µm-filtered; Atlanta Biologicals, cat. no. S11150H) Antibiotics 'pen-strep' (10,000 µ ml − 1 penicillin, 10 mg ml − 1 streptomycin; Invitrogen, cat. no. 15140) FTIs, GGTIs (we use inhibitors mostly synthesized in-house, but some can also be purchased from commercial sources) DMSO (sterile-filtered, hybridoma-tested; Sigma, cat. no. D2650): most common solvent used for preparing stock solutions of PTIs
Step 1B (preparation of cell extracts for PT activity assays) H is a weak β-emitter, no special protective shielding is necessary, but it is a radiation hazard when inhaled, ingested via food or water, absorbed through the skin. A lab coat, gloves and protective eyewear should be worn. Wipe tests of the working area should be conducted after the completion of each experiment.
Step 1D (preparation of cDNA-encoding candidate PT substrates)
Optional H is a weak β-emitter, no special protective shielding is necessary, but it is a radiation hazard when inhaled, ingested via food or water, when absorbed through the skin. A lab coat, gloves and protective eyewear should be worn. Wipe tests of the working area should be conducted after the completion of each experiment. Table 2 Secondary antibodies that are peroxidase-conjugated and affinity-purified, see Table 3 Step 2D (immunoprecipitation of [
H]-labeled proteins)
Igepal CA-360 (NP-40 substitute; Sigma, cat. no. I3021) Sodium deoxycholate (Pierce, cat. no. 89904)
Step 2E (in vitro transcription-translation-prenylation) TnT reticulocyte lysate system (Promega, cat. nos. L4600, L4610, L4950, L5010, L5020)  crItIcal Which system to purchase depends on the nature of the RNA polymerase promoter used in the plasmid of interest. Rnasin ribonuclease inhibitor (Promega, cat. no. N2111) Nuclease-free water (Promega, cat. no. P1193) l-[ S is a relatively weak β-emitter, and thus no special protective shielding is necessary, but it is a radiation hazard when inhaled, ingested via food or water, absorbed through the skin. A lab coat, gloves and protective eyewear should be worn. A particular danger associated with 35 S is that this isotope is extremely volatile. Therefore, predetermined amounts of 35 S should be removed from the radioactive REAGENT SETUP FTI and GGTI Most PTIs we have investigated are soluble in DMSO up to concentrations of 100 mM. Ideally, weigh as little drug powder as possible ( <10 mg) in a 1.7-ml tube, and add DMSO to arrive at a final concentration of 100 mM. Store in small aliquots at − 20 °C . The stability of each compound has to be determined empirically (see TROUBLESHOOTING). Cell sonication buffer Cell sonication buffer is prepared using 50 mM Tris/HCl (pH 7.5), 1 mM EDTA, 1 mM EGTA and 1 mM DTT. Store at 4 °C indefinitely. Just before use, add protease inhibitor cocktail tablets and 2 mM PMSF. Tissue lysis buffer (T-PER reagent) Store T-PER reagent at room temperature (RT; 21 °C) indefinitely. Just before use, add 2 mM Na 3 VO 4 , 2 mM PMSF and 6.4 mg ml − 1 4-nitrophenylphosphate to T-PER reagent protease inhibitor cocktail tablets. Tris-buffered saline Tris-buffered saline (TBS) is prepared using 20 mM Tris/HCl (pH 7.4) and 0.9% (wt/vol) NaCl. Store at RT for up to 1 month.
PT reaction buffer (3×) Mix the following components to the indicated final concentrations: 100 mM Tris-Cl (pH 7.5), 150 µM ZnCl 2 , 60 mM KCl, 9 mM MgCl 2 and 3 mM DTT. Store at 4 °C. 6% (wt/vol) TCA/2% (wt/vol) SDS Mix 0.6 ml of 100% (wt/vol) TCA, 2 ml of 10% (wt/vol) SDS and 7.4 ml of ddH 2 O to a final volume of 10 ml. Store at RT indefinitely. PBS (pH 7.4) PBS is prepared using 137 mM NaCl, 2.7 mM KCl, 10 mM Na 2 HPO 4 Step 1D).  crItIcal step Perform Steps 1A(i) and 1A(ii) using sterile techniques.  crItIcal step If you plan to perform enzyme activity assays (Step 1B), or prepare cell lysates for the EMSA (Step 2B) or subcellular fractionation (Step 2C), consider that the initial plating density should be optimized for each cell line in such a way that by the end of the incubation period (≥72 h) the cells will not have reached confluency. In most cases, 60-mm plates are big enough to yield sufficient protein for western blot analysis, but occasionally, 100-mm dishes may be required.  crItIcal step If you plan to label cells with [ 3 H]-MVA (Step 1D), it is advisable to set up cells at two split ratios and choose the culture closest to 70% to 80% confluency for labeling. The cultures should contain between 0.5 × 10 6 and 0.5 × 10 7 cells. Note that the required number of cells to be plated and therefore the type of plate to be used depend on the abundance of the protein of interest and the efficiency of the subsequent immunoprecipitation step.
(ii) (Optional) On day 2, remove medium and in fresh medium add the PTI under investigation and incubate the cells for 24 to 72 h under the same conditions as in Step 1A(i). As negative controls, include untreated cells and cells treated with the vehicle to dissolve the drug. As positive control, add a known PTI at a concentration that inhibits prenylation by 50% to 100%. Note that PTI concentrations necessary to inhibit PT in cells may be an order of magnitude higher than those inhibiting PT in vitro.
Note that this step can be omitted if proceeding to Step 1D below. ? troublesHootInG (iii) To prepare extracts for PT activity assays, proceed with Step 1B. To label cells with [ (i) By using sterile technique, measure the weight of the tumor biopsies (ranging from 50 mg to 1 g); quickly return the tumor to ice by placing it into a prelabeled, precooled 50-ml sterile plastic tube. If you wish to perform PT activity assays (Step 2A) or mobility shift assays (Step 2B), add tissue lysis buffer. If you wish to perform subcellular fractionations (Step 2C), add TBS to normal or tumor tissue biopsies in a ratio of 20 ml per gram. ! cautIon For experiments involving human patients, informed consent must be obtained from all subjects. ! cautIon For experiments involving animals, national and institutional guidelines on animal welfare must be followed throughout. (ii) Cut the tissue into small pieces with a clean razor blade. (iii) By using the PowerGen* Model 125 homogenizer, homogenize the tumor biopsies, keeping tubes containing biopsies on ice during the homogenization. Wash blades of the homogenizer with 70% (vol/vol) ethanol 2-3 times, followed by one wash with ddH 2 O before and between samples. (iv) After homogenization, to perform enzyme activity assays (Step 2A) or mobility shift assays (Step 2B), centrifuge the sample tubes at 200g for 1 min at 4 °C to collect samples at the bottom of the tube. To pursue subcellular fractionation, centrifuge the homogenate at 1,000g for 5 min at 4 °C, discard the supernatant and proceed with Step 2C(iii).
(v) Transfer the homogenates from 50-ml tubes to 1.7-ml sterile prelabeled microcentrifuge tubes. Centrifuge the samples briefly to collect the contents at the bottom of the tubes.  pause poInt Boiled samples can be stored at − 20 °C until being further processed by SDS-PAGE. (xiii) Determine the subcellular distribution of the protein in question by running them on a 12.5% (wt/vol) SDS-PAGE gel, followed by western blotting with the appropriate antibody.  crItIcal step To assess the purity of the membrane and cytosolic fractions, it is crucial to probe for proteins that are known to be exclusively cytosolic, such as GAPDH or membrane bound, such as E-cadherin We prefer this approach because it has the added advantage that, unlike dried gels that are to be examined by fluorography, membranes do not crack and can be used to perform other assays, such as western blotting ! cautIon Exposure times of up to 3 months may sometimes be required. (e) In vitro prenylation using in vitro transcription-translation systems • tIMInG 6 h for step 2e(i-iv), up to 3 months for step 2e(v) (i) According to Promega Technical Bulletin 126 ((http://www.promega.com/resources/protocols/technical-bulletins/0/ tnt-coupled-reticulocyte-lysate-system-protocol/), assemble the components of the transcription-translation reaction mix on ice. These include the reticulocyte lysate, reaction buffer, the appropriate RNA polymerase, amino acid mix minus leucine or methionine, as well as a RNase inhibitor. • tIMInG
Step 1A, Growth of mammalian cells including drug treatment: 3-4 d
Step 1B, Preparation of cell extracts for PT activity assays: ~4 h
Step 1C, Preparation of tumor biopsy extracts containing PT: ~3 h
Step 1D, When treating cells, animals or, as in this example, humans, it is crucial to determine the enzyme activity targeted by the given drug. This figure shows that FT activity in PBMCs from patients with myelodysplastic syndrome is inhibited after treatment with the FTI tipifarnib. PBMCs from patients before (0) and during treatment (on days 2 and 7, for example) were prepared as described in
Step 1B, and FT activity was measured as described in Step 2A. CR, complete remission; HI, hematological improvement; NR, no response; PD, progressive disease; PR, partial remission. There appears to be no obvious correlation between the response and the degree of FT inhibition. GGT-1 activity, which was measured concurrently, was not inhibited by tipifarnib (reproduced from ref. 28 , this study was conducted in accordance with institutional internal review board policy after obtaining written informed consent from participating patients). Figure 3 | Typical results from EMSAs described in Step 2B. After treatment of cells with PTIs, the protein under investigation will accumulate in the unprocessed (unprenylated) form (U), at the expense of the prenylated species (P). To verify whether a PTI has functioned properly in a given experiment, we recommend checking the prenylation status of the FT substrate HDJ-2 and the GGT-1 substrate Rap1A. This can be detected by a change in electrophoretic mobility (HDJ-2) or with antibodies specific for the unprenylated form (Rap1A), using 7.5 or 15.0% (wt/vol) acrylamide gels. Note that substrates for FT, GGT-1 or both PTs react differently to experimental drug treatment. After treatment of cells with an FTI, a GGTI or a combination of the two, one can envision three different outcomes: exclusively farnesylated proteins (HDJ-2) respond to an FTI, exclusively geranylgeranylated proteins (Rap1A) respond to a GGTI, whereas alternatively prenylated proteins (K-Ras, reproduced from ref. 61 ) only respond to inhibition of both enzymes. ]MVA labeling of intact cells in the absence or presence of a PTI, followed by immunoprecipitation of the protein of interest. For proteins that do not change their mobility, e.g., RhoA, their prenylation can be assessed by studying their distribution between membrane and cytosolic fractions 79 (Fig. 4) . Finally, in Figure 5 , we present the results of an in vitro transcription-translationprenylation experiment 3 .
RalA-Q72L Figure 5 | Typical results from in vitro transcription-translation-prenylation assays described in Step 2E. In the example shown, wild-type RalA (CaaX box: CCIL) and GTP-locked mutant RalA-Q72L (CaaX box: CCIL) were geranylgeranylated, but not farnesylated in vitro. However, mutants with a C-terminal CCIS motif were farnesylated instead, whereas mutants with a C-terminal SCIL motif were resistant to prenylation (reproduced from ref.
3). coMpetInG FInancIal Interests The authors declare no competing financial interests.
